Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Glioma 4Wilms Tumor 2Urothelial Cancer 2Rhabdoid Tumor 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Carcinoma, Transitional Cell 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1

Interventions

Gemcitabine 10Mitomycin 6Docetaxel 5erdafitinib 4durvalumab 4BCG Vaccine 4dodecyl maltoside 3Cystoscopy 3ALT-803 2viscum album peptide 1tremelimumab 1pirarubicin 1monalizumab 1hydroxycamptothecinum 1chondroitin sulfate, sodium hyaluronate drug combination 1Watchful Waiting 1Transurethral Resection of Bladder 1Patient Discharge 1Paclitaxel 1Mitozytrex 1Magnetic Resonance Spectroscopy 1Injections 1Hyaluronic Acid 1House Calls 1Home Care Services 1Epirubicin 1Drainage 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Chondroitin Sulfates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × erdafitinib × 90 days × Clear all
NCT05316155 2026-06-05

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Janssen Research & Development, LLC

Phase 1/2 Recruiting
235 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-06-05

MoonRISe-1

Janssen Research & Development, LLC

Phase 3 Recruiting
641 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-06-05

MoonRISe-3

Janssen Research & Development, LLC

Phase 3 Recruiting
220 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04917809 2026-04-22

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡